Study of Calcium Carbonate to Help Improve Labor Contractions and Delivery Outcomes in Women Undergoing Labor Induction or Augmentation

What this Trial Is About

Researchers are evaluating the use of calcium carbonate as a medication to help improve contractions during labor. This study focuses on women undergoing labor induction or augmentation, aiming to see if calcium carbonate can lead to stronger contractions, increase vaginal delivery rates, and improve delivery outcomes. The trial is a phase 4 study sponsored by Weill Medical College of Cornell University. Participants will be randomly assigned to one of two groups. The control group will receive standard-dose synthetic oxytocin Pitocin alone for labor induction or augmentation. The experimental group will receive oral calcium carbonate 500 mg every 4 hours alongside the standard-dose synthetic oxytocin infusion. Treatment will continue during hospitalization, which typically lasts about 5 days. During the study, participants will be monitored for adherence to the intervention, labor duration, mode of delivery, postpartum bleeding, treatment-related side effects, and maternal and neonatal health measures such as APGAR scores and cord blood gases. Data on race and ethnicity will also be collected. Safety assessments will continue for up to six weeks after delivery. The total participation duration includes hospitalization of approximately 5 days and follow-up monitoring.

Calcium Carbonate to Augment Labor Contractions